In8bio Valuation
| INAB Stock | USD 2.17 0.03 1.36% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. In8bio Inc owns a latest Real Value of $2.5 per share. The recent price of the firm is $2.17. Our model calculates the value of In8bio Inc from analyzing the firm fundamentals such as EBITDA of (27.78 M), return on asset of -0.73, and Shares Outstanding of 3.44 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting In8bio's valuation include:
Undervalued
Today
Please note that In8bio's price fluctuation is dangerous at this time. Calculation of the real value of In8bio Inc is based on 3 months time horizon. Increasing In8bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since In8bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of In8bio Stock. However, In8bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.17 | Real 2.5 | Target 3.59 | Hype 2.16 | Naive 2.2 |
The real value of In8bio Stock, also known as its intrinsic value, is the underlying worth of In8bio Inc Company, which is reflected in its stock price. It is based on In8bio's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of In8bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of In8bio Inc helps investors to forecast how In8bio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of In8bio more accurately as focusing exclusively on In8bio's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use In8bio's intrinsic value based on its ongoing forecasts of In8bio's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against In8bio's closest peers. If more than one evaluation category is relevant for In8bio we suggest using both methods to arrive at a better estimate.
In8bio Cash |
|
In8bio Valuation Trend
Comparing In8bio's enterprise value against its market capitalization is a good way to estimate the value of In8bio Inc uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
In8bio Total Value Analysis
In8bio Inc is currently forecasted to have valuation of (142.01 K) with market capitalization of 7.47 M, debt of 5.03 M, and cash on hands of 25.74 M. The negative valuation of In8bio may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the In8bio fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(142.01 K) | 7.47 M | 5.03 M | 25.74 M |
In8bio Asset Utilization
One of the ways to look at asset utilization of In8bio is to check how much profit was generated for every dollar of assets it reports. In8bio owns a negative utilization of current and long term assets of -0.73 %, losing $0.007325 for each dollar of current and long term assets held by the firm. Discouraging asset utilization attests that the company is being less competent with each dollar of current and long term assets it owns. Strictly speaking, asset utilization of In8bio Inc shows how wasteful it operates for each dollar spent on its current and long term assets.In8bio Ownership Allocation
In8bio owns 4.0 % of its outstanding shares held by insiders and 20.98 % owned by institutions.In8bio Profitability Analysis
Net Loss for the year was (30.44 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates In8bio's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in In8bio and how it compares across the competition.
About In8bio Valuation
The stock valuation mechanism determines In8bio's current worth on a weekly basis. Our valuation model uses a comparative analysis of In8bio. We calculate exposure to In8bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of In8bio's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -2.3 M | -2.1 M |
In8bio Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 53.5 M |
In8bio Current Valuation Indicators
Valuation refers to the process of determining the present value of In8bio Inc and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value In8bio we look at many different elements of the entity such as In8bio's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as In8bio, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use In8bio's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes In8bio's worth.Complementary Tools for In8bio Stock analysis
When running In8bio's price analysis, check to measure In8bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy In8bio is operating at the current time. Most of In8bio's value examination focuses on studying past and present price action to predict the probability of In8bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move In8bio's price. Additionally, you may evaluate how the addition of In8bio to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |